Sublocade vs SL Buprenorphine after Release from Jail
The Carlat Addiction Treatment Report, Volume 10, Number 6&7, August 2022
https://www.thecarlatreport.com/newsletter-issue/catr10n6-7/
Issue Links: Learning Objectives | Editorial Information
Topics: Buprenorphine | Incarceration | long-acting buprenorphine | OUD
Peter J. Farago, MD.
Dr. Farago, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
The period immediately following release from incarceration is associated with an elevated risk of overdose among those with opioid use disorder. In this randomized trial, researchers were able to show that long-acting injectable buprenorphine (Sublocade) is a feasible and effective treatment for this high-risk population.
You can't view details of this content, please login or buy subscription here